[Featured Stock] AB Pro Bio Shows Effectiveness of COVID-19 Treatment on Omicron... US FDA Emergency Approval Anticipated

[Asia Economy Reporter Minwoo Lee] AB Pro Bio's stock price is on the rise. Expectations have grown following news that the COVID-19 neutralizing antibody candidate 'ABP-310' is effective against the new variant 'Omicron.'

As of 9:56 a.m. on the 10th, AB Pro Bio's stock price recorded 1,130 KRW, up 19.45% compared to the previous day. The stock price appears to have surged due to positive news regarding Omicron.

AB Pro recently announced that their research on Omicron, Delta, and Omicron (SARS-CoV) confirmed the efficacy of 'ABP-310' against the Omicron variant as well.

Ian Chan, CEO of AB Pro Bio, stated, "This study is an initial verification of whether neutralizing antibody treatments can be effective across various geographic origins and timeframes. We designed ABP-310 to have the best possible efficacy and safety against all currently circulating variants while also being capable of responding to future variants."

He continued, "Ultimately, we plan to apply for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to help treat patients and curb the ongoing COVID-19 pandemic."

This content was produced with the assistance of AI translation services.